Cognition Therapeutics (CGTX) Total Non-Current Liabilities (2020 - 2024)

Cognition Therapeutics (CGTX) has 5 years of Total Non-Current Liabilities data on file, last reported at $13.1 million in Q3 2024.

• Quarterly Total Non-Current Liabilities rose 33.02% year-over-year to $13.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $13.1 million (up 33.02% YoY) and the FY2023 annual result came in at $10.7 million, up 25.9% from the prior year.
• Total Non-Current Liabilities climbed to $13.1 million in Q3 2024 per CGTX's latest filing, from $11.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $17.7 million in Q4 2020 and bottomed at $7.2 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $9.8 million (2023), against an average of $10.3 million.
• The widest annual swing landed in 2021, when Total Non-Current Liabilities tumbled 55.63%; it then soared 33.3% in 2024.
• Tracing CGTX's Total Non-Current Liabilities over 5 years: stood at $17.7 million in 2020, then plunged by 55.63% to $7.9 million in 2021, then increased by 7.96% to $8.5 million in 2022, then rose by 25.9% to $10.7 million in 2023, then increased by 22.53% to $13.1 million in 2024.
• Per Business Quant, the three latest CGTX Total Non-Current Liabilities figures stand at $13.1 million (Q3 2024), $11.4 million (Q2 2024), and $10.0 million (Q1 2024).

Peer Comparison